BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to undenatured virus-free bio logically active protein-containing compositions. More especially, this invention relates to the inactivation of viruses, especially lipid coated viruses, e.g., hepatitis B in human blood, blood component, blood plasma or any fraction, concentrate or derivative thereof containing blood proteins or non-blood sources including normal or cancer cells, the exudate from cancer or normal cells grown in culture, hybridomas, in products from gene splicing (DNA), etc., by the use of di-or trialkyl phos phates, and to the resultant products. In particular, this invention relates to blood plasma or other plasma pro tein-containing compositions which are to be rendered substantially free of hepatitis B and/or non-A and non-B hepatitis or other viral infectivity, such blood plasma or fractions thereof having valuable labile prote ins, such as, for example, factor VIII.
DISCUSSION OF PRIOR ART
Numerous attempts have been made to inactivate viruses such as hepatitis B virus (HBV) in mammalian, especially human, blood plasma. It is the practice in some countries to effect inactivation of the hepatitis B virus in the blood plasma by contacting the plasma with a viral inactivating agent of the type which crosslinks with the proteinaceous portion of hepatitis B virus, or which interacts with the nucleic acid of the virus. For instance, it is known to attempt to inactivate hepatitis B virus by contact with an aldehyde such as formalde hyde whereby crosslinking to the protein is effected and the hepatitis B virus is inactivated. It is also known to effect inactivation of the virus by contact with beta propiolactone (BPL), an agent which acts on the nu cleic acid of the virus. It is further known to use ultravi olet (UV) light, especially after a beta-propiolactone treatment.
Unfortunately, these agents often alter, denature or destroy valuable protein components especially so called "labile' blood coagulation factors of the plasma under conditions required for effective inactivation of virus infectivity. For instance, in such inactivation pro cedures, factor VIII is inactivated or denatured to the extent of 50-90% or more of the factor VIII present in the untreated plasma. Because of the denaturing effects of these virus inactivating agents, it is necessary in the preparation of derivatives for administration to patients to concentrate large quantities of plasma so that the material to be administered to the patient once again has a sufficient concentration of the undenatured protein for effective therapeutic treatment. This concentration, however, does not affect reduction of the amount of denatured protein. As a result, the patient not only receives the undenatured protein but a quantity of dena tured protein often many times that of the undenatured protein.
For instance, in the inactivation of hepatitis B virus in human blood plasma by beta-propiolactone, there is 2 obtained as a result thereof, a plasma whose factor VIII has been 75% inactivated. The remaining 25% of the factor VIII is therefore present in such a small concen tration, as a function of the plasma itself, that it is neces sary to concentrate large quantities of the factor VIII to provide sufficient concentration to be of therapeutic value. Since such separation techniques do not effi ciently remove denatured factor VIII from undena tured factor VIII, the material administered to the pa tent may contain more denatured protein than undena tured protein. Obviously, such inactivation is valuable from a standpoint of diminishing the risk of hepatitis virus infection. However, it requires the processing of large quantities of plasma and represents significant loss of valuable protein components. Furthermore, adminis tration of large amounts of denatured proteins may render these antigenic to the host and thus give rise to autoimmune diseases, or perhaps, rheumatoid arthritis.
The loss of these valuable protein components is not limited to factor VIII, one of the most labile of the valuable proteins in mammalian blood plasma. Similar protein denaturation is experienced in respect of the following other valuable plasma components: coagula tion factors II, VII, IX, X; plasmin, fibrinogen (factor I) IgM, hemoglobin, interferon, etc. Factor VIII, however, it denatured to a larger extent than many of the other valuable proteins present in blood plasma.
As a result of the foregoing, except in the processing of serum albumin, a stable plasma protein solution which can withstand pasteurization, it is largely the practice in the United States in respect of the processing of blood proteins to take no step in respect of the steril ization for inactivation of viruses. As a result, recipients of factor VIII, gamma-globulin, factor IX, fibrinogen, etc., must accept the risk that the valuable protein com ponents being administered may be contaminated with hepatitis viruses as well as other infectious viruses. As a result, these recipients face the danger of becoming infected by these viruses and having to endure the dam age which the virus causes to the liver and other organ systems and consequent incapacitation and illness, which may lead to death.
The BPL/UV inactivation procedure discussed above has not so far been adopted in the United States for numerous reasons, one of which lies in the fact that many researchers believe the BPL is itself deleterious since it cannot be removed completely following the inactivation and thus may remain in plasma and plasma derivatives. BPL has been shown to be carcinogenic in animals and is dangerous even to personnel handling it.
Other methods for the inactivation of hepatitis B virus in the plasma are known, but are usually impracti cal. One method involves the addition of antibodies to the plasma whereby an immune complex is formed. The expense of antibody formation and purification add significantly to the cost of the plasma production; fur thermore, there is no assurance that a sufficient quantity of hepatitis B or non-A, non-B virus is inactivated. There is currently no test for non-A, non-B antibodies (although there is a test of the virus); hence, it is not possible to select plasma containing high titers of anti non-A, non-B antibody.
It is to be understood that the problems of inactiva tion of the viruses in plasma are distinct from the prob lems of inactivation of the viruses themselves due to the copresence of the desirable proteinaceous components of the plasma. Thus, while it is known how to inactivate 4, 820, 805 The present invention is directed to achieving three goals, namely, (1) a safe, (2) viral inactivated protein containing composition, (3) without incurring substan tial protein denaturation. As shown above, these three goals are not necessarily compatible since, for example, beta-propiolactone inactivates viral infectivity, but is unsafe and substances such as formaldehyde inactivate viruses, but also substantially denaturate the valuable plasma proteins, for example, factor VIII.
It, therefore, became desirable to provide a process for obtaining protein-containing compositions which does not substantially denature the valuable protein components therein and which does not entail the use of a proven carcinogenic agent. More especially, it is de sirable to provide blood protein-containing composi tions in which substantially all of the hepatitis viruses and other viruses present are inactivated and in which denatured protein such as factor VIII account for only 4. a small amount of the total amount of these proteins in the blood protein-containing composition.
It is a further object to provide products from cancer or normal cells or from fermentation processes follow ing gene insertion which are substantially free of virus, especially lipid-containing viruses.
SUMMARY OF THE INVENTION
It has now been discovered, quite surprisingly, that while most of the viral inactivating agents denature factor VIII and other valuable blood plasma proteins, that not all viral inactivating agents have such effect. It has been discovered that a protein-containing composi tion such as whole blood, blood cell proteins, blood plasma, a blood plasma fractionation precipitate, a blood plasma fractionation supernatant, cryoprecipi tate, cryosupernatant, or portion or derivative thereof or serum or a non-blood product produced from normal or cancerous cells (e.g. via recombinant DNA technol ogy) is contacted for a sufficient period of time with a dialkylphosphate or a trialkylphosphate that lipid con taining viruses such as the hepatitis viruses present in the composition are virtually entirely inactivated with out substantial denaturation of proteins therein. By con tacting blood protein mixture or concentrate thereof or fraction thereof with a di-or trialkylphosphate, fol lowed by removal of the di-or trialkylphosphate, hepa titis viruses can be substantially inactivated, e.g., to an inactivation of greater than 4 logs, while realizing a yield of protein activity to total protein of at least 80%.
By such procedures there is provided a blood protein containing composition such as mammalian whole blood, blood cell derivatives (e.g., hemoglobin, alpha interferon, T-cell growth factor, platelet-derived growth factor, etc.), plasminogen activator, blood plasma, blood plasma fraction, blood plasma precipitate (e.g., cryoprecipitate, ethanol precipitate or polyethyl ene glycol precipitate), or supernatant (e.g., cryosuper natant, ethanol supernatant or polyethylene glycol su pernatant), characterized by the presence of one or more blood proteins such as labile blood factor VIII having a total yield of protein activity to total protein of at least 80%, preferably at least 85%, more preferably 95% and most preferably 98% to 100%, said blood protein-containing composition having greatly reduced or virtually no hepatitis viruses. Virus in a serum is determined by infectivity titrations.
By the inactivation procedure of the invention, most if not virtually all of the hepatitis viruses contained therein would be inactivated. The method for determin ing infectivity levels by in vivo chimpanzees is dis cussed by Prince, A. M., Stephen, W., Brotman, B. and van den Ende, M. C., "Evaluation of the Effect of Beat propiolactone/Ultraviolet Irradiation (BPL/UV) Treatment of Source Plasma on Hepatitis Transmission by factor IV Complex in Chimpanzees, Thrombosis and Haemostasis', 44: 138-142, 1980. The hepatitis virus is inactivated by treatment with the di-or trialkylphosphate described herein, and is not inactivated because of inclusion in the plasma of anti bodies which bind with the hepatitis viruses and form immune complexes.
Inactivation of virus is obtained to the extent of at least "4 logs', i.e., virus in a serum is totally inactivated to the extent determined by infectivity studies where that virus is present in the untreated serum in such a concentration that even after dilution to 10, viral activ ity can be measured. Blood transfusions are used to treat anemia resulting from disease or hemorrhage, shock resulting from loss of plasma proteins or loss of circulating volume, dis eases where an adequate level of plasma protein is not maintained, for example, hemophilia, and to bestow passive immunization.
Whole blood must be carefully typed and cross matched prior to administration. Plasma, however, does not require prior testing. For certain applications, only a proper fraction of the plasma is required, such as factor VIII for treatment of hemophilia or von Wille brand's disease.
With certain diseases one or several of the compo nents of blood may be lacking. Thus, the administration of the proper fraction will suffice, and the other compo nents will not be "wasted' on the patient; the other fractions can be used for another patient. The separation of blood into components and their subsequent fraction ation allows the proteins to be concentrated, thus per mitting concentrates to be treated. Of great importance, too, is the fact that the plasma fractions can be stored for much longer periods than whole blood and they can be distributed in the liquid, the frozen, or the dried state.
Finally, it allows salvaging from blood banks the plasma portions of outdated whole blood that are unsafe for administration as whole blood.
Proteins found in human plasma include prealbumin, retinol-binding protein, albumin, alpha-globulins, beta globulins, gamma-globulins (immune serum globulins), the coagulation proteins (antithrombin III, prothrom bin, plasminogen, antihemophilic factor-factor VIIII, fibrin-stabilizing factor-factor XIII, fibrinogen), in munoglobins(immunoglobulins C, A, M, D, and E), and the complement components. There are currently more than 100 plasma proteins that have been described. A comprehensive listing can be found in "The Plasma Blood plasma fractionation generally involves the use of organic solvents such as ethanol, ether and polyethyl ene glycol at low temperatures and at controlled pH values to effect precipitation of a particular fraction containing one or more plasma proteins. The resultant supernatant can itself then be precipitated and so on until the desired degree of fractionation is attained. More recently, separations are based on chromato graphic processes. An excellent survey of blood frac tionation appears in Kirk-Othner's Encyclopedia of Chemical Technology, Third Edition, Interscience Pub lishers, Volume 4, pages 25 to 62, the entire contents of which are incorporated by reference herein.
The major components of a cold ethanol fraction ation are as follows: Polyethylene glycol has been used to prepare high purity AHD and non-aggregated ISG.
High risk products with respect to the transmission of hepatitis B and non-A, non-B are fibrinogen, AHF and prothrombin complex, and all other blood protein prep arations except immune serum globulin and, because they are pasteurized, albumin solutions. Hepatitis tests presently available can indicate the presence of hepatitis B surface antigen, but there is presently no screening test for non-A, non-B hepatitis.
The present invention is directed to contacting with di-or trialkylphosphate a blood protein-containing composition such as whole mammalian blood, blood cells thereof, blood cell proteins, blood plasma thereof, precipitate from any fractionation of such plasma, su pernatant from any fractionation of such plasma, cryo precipitate, cryosupernatant or any portions or deriva tives of the above that contain blood proteins such as, for example, prothrombin complex (factors II, VII, IX and X) and cryoprecipitate (factors I and VIII). The present invention is also concerned with contacting di or trialkylphosphate with a serum containing one or more blood proteins. Furthermore, the present inven tion is directed to contacting di-or trialkylphosphate with a blood protein-containing fraction containing at least one blood protein such as the following: factor II, factor VII, factor VIII, factor IX, factor X, fibrinogen and IgM. additionally, the present invention concerns contacting a cell lysate or proteins induced in blood cells with di-or trialkylphosphate.
Such blood protein-containing composition is con tacted with a dialkylphosphate or a trialkylphosphate having alkyl groups which contain 1 to 10 carbon atoms, especially 2 to 10 carbon atoms. Illustrative members of trialkylphosphates for use in the present invention include tri-(n-butyl)phosphate, tri-(t-butyl)-phosphate, tri-(n-hexyl)phosphate, tri-(2-ethylhexyl)-phosphate, tri-(n-decyl)phosphate, just to name a few. An especially preferred trialkylphosphate is tri-(nbutyl)phosphate. Mixtures of different trialkylphos phates can also be employed as well as phosphates hav ing alkyl groups of different alkyl chains, for example, ethyl, di(n-butyl) phosphate. Similarly, the respective dialkylphosphates can be employed including those of different alkyl group mixtures of dialkylphosphate. Fur thermore, mixtures of di-and trialkylphosphates can be employed.
Di-or Trialkylphosphates for use in the present in vention are employed in an amount between about 0.01 mg/ml and about 100 mg/ml, and preferably between about 0.1 mg/ml and about 10 mg/ml.
The di-or trialkylphosphate can be used with or without the addition of wetting agents. It is preferred, however, to use di-or trialkylphosphate in conjunction with a wetting agent. Such wetting agent can be added either before, simultaneously with or after the di-or trialkylphosphate contacts the blood protein-containing composition. The function of the wetting agent is to enhance the contact of the virus in the blood protein containing composition with the di-or trialkylphos phate. The wetting agent alone does not adequately inactivate the virus. Preferred wetting agents are non-toxic detergents. Contemplated nonionic detergents include those which disperse at the prevailing temperature at least 0.1% by weight of the fat in an aqueous solution containing the same when 1 gram detergent per 100 ml of solution is introduced therein. In particular there is contemplated detergents which include polyoxyethylene derivatives of fatty acids, partial esters of sorbitol anhydrides, for example, those products known commercially as "Tween 80", "Tween 20' and "polysorbate 80' and nonionic oil soluble water detergents such as that sold commercially under the trademark "Triton X 100' (oxyethylated alkylphenol). Also contemplated is so dium deoxychloate as well as the "Zwittergents' which are synthetic zwitterionic detergents known as "sul fobetaines' such as N-dodecyl-N, N-dimethyl-2-ammonio-lethane sulphonate and its congeners or non ionic detergents such as octyl-beta-D-glucopyranoside.
Substances which might enhance the effectiveness of alkylphosphates include reducing agents such as mer captoethanol, dithiothreitol, dithioerythritol, and dithi ooctanoic acid. Suitable nonionic surfactants are oxy ethylated alkyl phenols, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene acids, polyoxyethylene alcohols, polyoxyethylene oils and polyoxyethylene oxypropylene fatty acids. Some specific examples are The amount of wetting agent, if employed, is not crucial, for example, from about 0.001% to about 10%, preferably about 0.01 to 1.5%, can be used. Di-and trialkylphosphates may be used in conjunc tion with other inactivating agents such as alcohol or ethers with or without the copresence of wetting agents in accordance with copending application Ser. No. 368,250 entitled "Sterilized Plasma and Plasma Deriva tives and Process Therefor', assigned to the assignee hereof.
The ether or alcohol can be added in an amount of 1 to 50%, preferably 5 to 25% by weight, based on the volume of blood plasma, or concentrate or other blood plasma protein-containing composition to be treated. Particularly contemplated ethers for inactivation use in accordance with the invention are those having the formula wherein R and R2 are independently C1-C18 alkyl or alkenyl which can contain an O or Satom in the chain, prefera bly C1-C8 alkyl or alkenyl. Especially contemplated ethers are dimethyl ether, diethyl ether, ethyl propyl ether, methyl-butyl ether, methyl isopropyl ether and methyl isobutyl ether. 4,820,805 9 Alcohols contemplated include those of the formula ROH wherein R is a C to C18 alkyl or alkenyl radical which can contain one or more oxygen or sulfur atoms in the chain and which can be substituted by one or more hydroxyl groups, Especially contemplated alcohols are those where the alkyl or alkenyl group is between 1 and 8 atoms.
Particularly contemplated alcohols include methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol, n-pentanol and the isopentanols. Also contemplated are compounds such as ethylene glycol, 1,2-propylene gly col 1,3-propane diol, 1,4-butanediol, 2-hydroxyisobuta nol (2-methy, 1,2-dihydroxypropane).
Treatment of blood protein-containing compositions with trialkylphosphate is effected at a temperature be tween -5°C. and 70', preferably between 0° C. and 60 C. The time of such treatment (contact) is for at least 1 minute, preferably at least 1 hour and generally 4 to 24 hours. The treatment is normally effective at atmo spheric pressure, although subatmospheric and superat mospheric pressures can also be employed.
Normally, after the treatment, the trialkylphosphate and other inactivating agents, for example, ether, are removed, although such is not necessary in all instances, depending upon the nature of the virus inactivating agents and the intended further processing of the blood plasma protein-containing composition.
To remove ether from plasma the plasma is generally subjected to a temperature of 4° C. to 37 C. with a slight vacuum imposed to draw off residual ether. Pref.
erably means are provided to spread the plasma as a thin film to insure maximum contact and removal of the ether. Other methods for removal of ether inactivating agents include:
(1) bubbling of nitrogen gas; (2) diafiltration using ether insoluble, e.g. "TEF LON', microporous membranes which retain the plasma proteins; (3) absorption of desired plasma components on chro matographic or affinity chromographic supports; (4) precipitation, for example, by salting out of plasma proteins; (5) lyophilization, etc.
When alcohol or nonionic detergents are employed with the trialkylphosphate they are removed by (2) to (5) above.
Di-or trialkylphosphate can be removed as follows: (a) Removal from AHF can be effected by precipita tion of AHF with 2.2 molal glycine and 2.0M sodium chloride (b) Removal from fibronectin can be effected by binding the fibronectin on a column of insolubilized gelatin and washing the bound fibronectin free of rea gent.
Generally speaking, any ether present is initially re moved prior to removal of any detergent. The ether may be recovered for reuse by the use of suitable distil lation/condenser systems well known to the art.
Alcohol is normally removed together with deter gent. If the detergent includes both alcohol and ether, the ether is normally removed before the alcohol.
The process of the invention can be combined with still other modes of inactivating viruses including those for non-lipid coated viruses. For instance, a heating step can be effected in the presence of a protein stabilizer, 10 e.g., an agent which stabilizes the labile protein (AHF) against inactivation by heat. Moreover, the heating can be carried out using stabilizers which also tend to pro tect all protein, including components of the virus, against heat if the heating is carried out for a sufficient length of time, e.g., at least 5 hours and preferably at least 10 hours at a temperature of 50-70' C., especially 60° C. By such mode the virus is preferentially inacti vated, nevertheless, while the protein retains a substan tial amount, e.g., 280% of its protein activity. Of course, the best treatment can also be carried out simul taneously with the alkyl phosphate treatment.
The treatment of plasma or its concentrates, fractions or derivatives in accordance with the present invention can be effected using di-or trialkylphosphate immobi lized on a solid substance. The same can be fixed to a macro-molecular structure such as one of the type used as a backbone for ion exchange reactions, thereby per mitting easy removal of the trialkylphosphate from the plasma or plasma concentrate. Alternatively the phos phate can be insolubilized and immobilized on a solid support such as glass beads, etc., using silane or siloxane coupling agents.
The method of the present invention permits the pooling of human blood plasma and the treatment of the pooled human blood plasma in the form of such pooled plasma. It also permits the realization of blood product derivatives such as factor VIII, gamma globulin, factor IX or the prothrombin complex (factors II, VII, IX, X), fibrinogen and any other blood derivative including HBs.Ag used for the preparation of HBV vaccine, all of which contain little or no residual infective hepatitis or other viruses.
The present invention is directed, inter alia, to pro ducing a blood plasma blood plasma fractions, etc., which is substantially free of infectious virus, yet which contains a substantial amount of viable (undenatured) protein. More particularly, the present invention is di rected to inactivation of lipid-containing virus and pref erentially inactivation of hepatitis B and non-B, non-A virus. Other viruses inactivated by the present invention include, for example, cytomegaloviruses, Epstein Barr viruses, lactic dehydrogenase viruses, herpes group viruses, rhabdoviruses, leukoviruses, myxoviruses, al phaviruses, Arboviruses (group B), paramyxoviruses, arenaviruses, and coronaviruses.
According to the present invention, there is contem plated a protein-containing composition-a product produced from normal or cancerous cells or by normal or cancerous cells (e.g., via recombinant DNA technol ogy), such as mammalian blood, blood plasma, blood plasma fractions, precipitates from blood fractionation and supernatants from blood fractionation having an extent of inactivation of virus greater than 4 logs of virus such as hepatitis B and non-A, non-B, and having a yield of protein activity to total protein of at least 80%, preferably at least 95% and most preferably 98% to 100%.
Further contemplated by the present invention is a composition containing factor VIII which is substan tially free of hepatitis virus to the extent of having an inactivation of greater than 4 logs of the virus and a yield of protein activity to total protein of at least 80%, preferably at least 85%, more preferably at least 95% and most preferably 98% to 100%.
The process of the present invention has been de scribed in terms of treatment of plasma, plasma frac 4,820,805 11 tions, plasma concentrates or components thereof. The process, however, is also useful in treating the solid components of blood, lysates or proteins secreted by cells. Thus, also contemplated are treatment of platelet concentrates, white cell (leukocyte) concentrates, and leukocyte-poor packed red cells as well as platelet rich plasma, platelet concentrates and platelet poor plasma including packed cell masses comprising the white buffy coat consisting of white blood cells above packed red cells. Also contemplated is the treatment of masses containing concentrates of granulocytes, monocytes, interferon, and transfer factor.
One can treat plasma itself according to the present invention or fresh frozen plasma, thawed frozen plasma, cryoprecipitate, cryosupernatants or concentrates from frozen plasma as well as dilution products thereof.
By the same manipulation steps discussed above virus present in products of normal or cancerous cells can be inactivated while retaining labile protein activity in such products. For instance, by the same di-or trialkyl phosphate treatment one can inactivate products pro duced using normal or cancer cells, the exudate from Lymphokine activity is measured biologically in cell systems, typically by assaying their biological activity in cell cultures.
Protein activity generally is determined by the known and standard modes for determining the activity of the protein or type of protein involved.
In order to more fully illustrate the nature of the invention and the manner of practicing the same, the following non-limiting examples are presented. The results for Example 1 are shown below in Table   I:  TABLE I  Time In FIG. 1, FIG. 2, and FIG. 3 , the results of Example 1 are plotted and compared to virus inactivation with ether (20%)/Tween 80 (1%). It is seen that for VSV (FIG. 1) . Sindbis (FIG. 2) and Sendai (FIG. 3) , inactiva tion was greater (lower log titer value) for treatment according to the present invention (with TNBP) than with ether/Tween 80 treatment.
In Table II , the effect of a "Tween 80' alone in the inactivation of viruses is shown. The data shows that little if any inactivation is due to "Tween 80'. Example 1 was repeated, but at 22 C. The results for Example 2 are summarized below in Table III:   TABLE III  Tempera- The present invention may be embodied in other specific forms without departing from the spirit or es sential attributes thereof and, accordingly, reference should be had to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.
We claim:
1. A process for obtaining a protein-containing com position which is substantially free of lipid-containing viruses without incurring substantial denaturation of any labile proteins contained therein, comprising con tacting said protein-containing composition with an effective amount of di-or trialkylphosphate for a suffi cient period of time, wherein said protein-containing composition is the product of a cancerous cell or the product of gene splicing.
2. A process according to claim 1, wherein the pro tein-containing composition is a product of a cancerous cell.
3. A process according to claim 1, wherein the pro tein-containing composition is a product of gene splic ing. 
Attesting Officer
Commissioner of Patents and Trademarks
